Intervene in the sickle cell
disease (SCD) cascade^1,2

Oxbryta directly inhibits hemoglobin S (HbS)
polymerization and subsequent red blood cell
(RBC) sickling to reduce hemolysis and improve
anemia

Watch how Oxbryta
intervenes

Review representative
blood smear imagery

Intervene in the
sickle cell disease (SCD) cascade^1,2

Oxbryta directly inhibits hemoglobin S (HbS) polymerization and subsequent red blood cell (RBC) sickling to reduce hemolysis and improve anemia

Watch how Oxbryta
intervenes

Review representative
blood smear imagery

Efficacy Results

Examine 24- and 72-week data from the HOPE trial

Dosing

View dosing schedule and adjustments

Access & Support

Discover the GBT Source^® Solutions program

Browse video resources

SCD medical experts discuss Oxbryta and appropriate patient cases

Participants were compensated for their time.

INDICATIONS AND USAGE

Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY
INFORMATION

Contraindications

Oxbryta is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients.

INDICATIONS AND USAGE

Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications

Oxbryta is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients.

Warnings and precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions after administration of Oxbryta have occurred in <1% of patients treated. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia.

If hypersensitivity reactions occur, discontinue Oxbryta and administer appropriate medical therapy. Do not reinitiate Oxbryta in patients who experience these symptoms with previous use.

Laboratory Test Interference

Oxbryta administration may interfere with measurement of Hb subtypes by (HbA, HbS, and HbF) HPLC. If precise quantitation of Hb species is required, chromatography should be performed when the patient is not receiving Oxbryta therapy.

Adverse reactions

Clinical Trials Experience

Serious adverse reactions occurred in 3% (3/88) of patients receiving Oxbryta 1,500 mg, which included headache, drug hypersensitivity, and pulmonary embolism occurring in 1 patient each.

Adverse Reactions (≥10%) in patients receiving Oxbryta with a difference of >3% compared to placebo: Headache (26% vs. 22%), Diarrhea (20% vs. 10%), Abdominal Pain (19% vs. 13%), Nausea (17% vs. 10%), Fatigue (14% vs. 10%), Rash (14% vs. 10%), and Pyrexia (12% vs. 7%).

Drug interactions

Sensitive CYP3A4 Substrates

Voxelotor increased the systemic exposure of midazolam (a sensitive CYP3A4 substrate). Avoid co-administration with sensitive CYP3A4 substrates with a narrow therapeutic index. If unavoidable, consider dose reduction of the CYP3A4 substrate(s).

Strong CYP3A4 Inhibitors or Fluconazole

Co-administration of strong CYP3A4 inhibitors or fluconazole may increase voxelotor plasma concentrations and may lead to increased toxicity. Avoid co-administration of strong CYP3A4 inhibitors or fluconazole. Decrease Oxbryta dosage if unavoidable.

Strong or Moderate CYP3A4 Inducers

Co-administration of strong or moderate CYP3A4 inducers may decrease voxelotor plasma concentrations and may lead to reduced efficacy. Avoid co-administration of strong or moderate CYP3A4 inducers. Increase the Oxbryta dosage if unavoidable.

USE IN SPECIFIC POPULATIONS

Lactation

Because of the potential for serious adverse reactions in the breastfed child, including changes in the hematopoietic system, advise patients not to breastfeed while taking Oxbryta and for at least 2 weeks after the last dose.

Recommended Dosage for Hepatic Impairment

Severe hepatic impairment increases voxelotor exposures. Reduce dose to 1,000 mg orally once daily for severe hepatic (Child Pugh C) impairment.

Please see Full Prescribing Information for Oxbryta for more information.

References: 1. Oxbryta Full Prescribing Information. South San Francisco, CA: Global Blood Therapeutics, Inc.; 11/2019. 2. Vichinsky E, Hoppe CC, Ataga Kl, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509-519. 3. Kato GJ, Steinberg MH, Gladwin MT. lntravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750-760. 4. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364(9442):1343-1360. 5. Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127(7):820-828. 6. Kapoor S, Little JA, Pecker LH. Advances in the treatment of sickle cell. Mayo Clin Proc. 2018;93(12):1810-1824. 7. Howard J. Hemmaway CJ, Telfer P, et al. A phase 1/2 ascending dose study and open-label extension study of voxelotor in pateitns with sickle cell disease. Blood. 2019;133(17):1865-1875. 8. Data on file, Global Blood Therapeutics. 04/2021.

References: 1. Oxbryta Full Prescribing Information. South San Francisco, CA: Global Blood Therapeutics, Inc.; 11/2019. 2. Data on file, Global Blood Therapeutics. 02/2020.

References: 1. Oxbryta Full Prescribing Information. South San Francisco, CA: Global Blood Therapeutics, Inc.; 11/2019.

Intervene in the sickle cell disease (SCD) cascade1,2

Oxbryta directly inhibits hemoglobin S (HbS) polymerization and subsequent red blood cell (RBC) sickling to reduce hemolysis and improve anemia

Intervene in the sickle cell disease (SCD) cascade1,2

Oxbryta directly inhibits hemoglobin S (HbS) polymerization and subsequent red blood cell (RBC) sickling to reduce hemolysis and improve anemia

Efficacy Results

Dosing

Access & Support

Browse video resources

SCD medical experts discuss Oxbryta and appropriate patient cases

Get the latest information about Oxbryta delivered to your inbox

Intervene in the sickle cell
disease (SCD) cascade^1,2

Oxbryta directly inhibits hemoglobin S (HbS)
polymerization and subsequent red blood cell
(RBC) sickling to reduce hemolysis and improve
anemia

Intervene in the
sickle cell disease (SCD) cascade^1,2